Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b in Adult COVID-19 Patients With Comorbidities
NCT05808322Phase 3Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Time from randomization to the achievement of Ct value ≥30 in SARS-CoV-2 quantitative RT-PCR. Status: unknown.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05808322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808322.